Vascular Malformations Drug Pipeline Analysis Report 2025
Description
Vascular malformations, also known as abnormal blood vessel forms, can happen anywhere in the body. They are caused by improper blood vessel formation during fetal growth and are usually present from birth. These malformations include capillary malformations, lymphatic malformations, venous malformations, and arteriovenous malformations (AVMs). Uneven, twisted blood artery networks are their defining feature, and they can cause symptoms including discomfort, bleeding, edema, and, in certain situations, functional impairment. Depending on the kind and degree, vascular abnormalities can develop gradually over time and be treated with laser therapy, embolization, or surgery. Moreover, the rising prevalence of the disorder is anticipated to positively impact the pipeline landscape for vascular malformations emerging drugs.
Report Coverage
The Vascular Malformations Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into vascular malformations therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vascular malformations. The vascular malformations report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The vascular malformations pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with vascular malformations treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to vascular malformations.
Vascular Malformations Drug Pipeline Outlook
While managing vascular malformations, there is significant emphasis on treating aberrant blood vessel formation. Treatment options include laser therapy to target blood arteries, embolization to decrease blood supply to the malformation, and surgical excision for lesions that are accessible. Additionally, the signaling mechanisms that cause aberrant vascular growth can be blocked by pharmaceutical treatments like rapamycin or angiogenesis inhibitors. Improving results, lowering complications, and minimizing functional damage all depend on early detection and tailored treatment.
Although oligonucleotides and peptides show promise, small molecules are used more frequently because of their proven efficacy in treating vascular disorders and their capacity to enter tissues. Small molecules are the most recommended molecule type as they can target pathways, such as the vascular endothelial growth factor (VEGF) signaling pathway, that are implicated in the aberrant formation of blood vessels. Further, the rising focus on the development of vascular malformations emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Vascular Malformations Epidemiology
A common anomaly in blood vessel development, vascular malformations (VAMs) impacts 1.2% to 1.5% of children worldwide. According to reports, there are 9.85 incidences of extracranial vascular malformations per 100,000 people per year, with venous and lymphatic malformations being the most prevalent kinds. The incidence of venous abnormalities alone is 1 to 2 per 10,000 neonates. Even while many vascular malformations are benign, some might cause serious health issues, which emphasizes the importance of awareness and efficient management techniques.
Vascular Malformations – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vascular malformations drug candidates based on several segmentations including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials, with a substantial number of vascular malformation drugs undergoing clinical development.
Vascular Malformations – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under vascular malformations pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The vascular malformations report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Vascular Malformations.
Vascular Malformations Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the vascular malformations drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Vascular Malformations therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Vascular Malformations clinical trials:
Major drugs currently in the drug pipeline are as follows:
Drug: Sirolimus
Sponsored by Vascular Therapies, Inc., the objective of this multicenter clinical trial is to investigate the efficacy and safety of the vascular malformations drug candidate Sirolimus in the affected patients. The study is under Phase III clinical development.
Drug: REC-994
Recursion Pharmaceuticals is conducting a Phase II study aimed at examining the efficacy of the investigational drug REC-994 for the treatment of vascular malformations. The study is under Phase II clinical development.
Reasons To Buy This Report
The Vascular Malformations Drug Report provides a strategic overview of the latest and future landscape of treatments for vascular malformations. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the vascular malformations pipeline insights.
Key Questions Answered in the Vascular Malformations – Pipeline Insight Report
Global Cancer Therapeutics Market
Global Clinical Trials Market
Report Coverage
The Vascular Malformations Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into vascular malformations therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vascular malformations. The vascular malformations report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The vascular malformations pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with vascular malformations treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to vascular malformations.
Vascular Malformations Drug Pipeline Outlook
While managing vascular malformations, there is significant emphasis on treating aberrant blood vessel formation. Treatment options include laser therapy to target blood arteries, embolization to decrease blood supply to the malformation, and surgical excision for lesions that are accessible. Additionally, the signaling mechanisms that cause aberrant vascular growth can be blocked by pharmaceutical treatments like rapamycin or angiogenesis inhibitors. Improving results, lowering complications, and minimizing functional damage all depend on early detection and tailored treatment.
Although oligonucleotides and peptides show promise, small molecules are used more frequently because of their proven efficacy in treating vascular disorders and their capacity to enter tissues. Small molecules are the most recommended molecule type as they can target pathways, such as the vascular endothelial growth factor (VEGF) signaling pathway, that are implicated in the aberrant formation of blood vessels. Further, the rising focus on the development of vascular malformations emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Vascular Malformations Epidemiology
A common anomaly in blood vessel development, vascular malformations (VAMs) impacts 1.2% to 1.5% of children worldwide. According to reports, there are 9.85 incidences of extracranial vascular malformations per 100,000 people per year, with venous and lymphatic malformations being the most prevalent kinds. The incidence of venous abnormalities alone is 1 to 2 per 10,000 neonates. Even while many vascular malformations are benign, some might cause serious health issues, which emphasizes the importance of awareness and efficient management techniques.
Vascular Malformations – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vascular malformations drug candidates based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Oligonucleotide
- Peptides
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials, with a substantial number of vascular malformation drugs undergoing clinical development.
Vascular Malformations – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under vascular malformations pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The vascular malformations report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Vascular Malformations.
Vascular Malformations Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the vascular malformations drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Vascular Malformations therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Vascular Malformations clinical trials:
- Vascular Therapies, Inc.
- Recursion Pharmaceuticals Inc.
- Vesper Medical, Inc.
- Sonavex, Inc.
- VenoStent
- Medtronic Endovascular
- VentureMed Group Inc.
Major drugs currently in the drug pipeline are as follows:
Drug: Sirolimus
Sponsored by Vascular Therapies, Inc., the objective of this multicenter clinical trial is to investigate the efficacy and safety of the vascular malformations drug candidate Sirolimus in the affected patients. The study is under Phase III clinical development.
Drug: REC-994
Recursion Pharmaceuticals is conducting a Phase II study aimed at examining the efficacy of the investigational drug REC-994 for the treatment of vascular malformations. The study is under Phase II clinical development.
Reasons To Buy This Report
The Vascular Malformations Drug Report provides a strategic overview of the latest and future landscape of treatments for vascular malformations. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the vascular malformations pipeline insights.
Key Questions Answered in the Vascular Malformations – Pipeline Insight Report
- What is the current landscape of vascular malformations disease pipeline drugs?
- Which companies/institutions are developing vascular malformations disease emerging drugs?
- How many phase II drugs are currently present in vascular malformations disease pipeline drugs?
- Which company is leading the vascular malformations disease pipeline development activities?
- What is the current vascular malformations disease therapeutic assessment?
- What are the opportunities and challenges present in the vascular malformations disease drug pipeline landscape?
- What is the efficacy and safety profile of vascular malformations disease pipeline drugs?
- Which companies/institutions are involved in vascular malformations disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in vascular malformations disease?
Global Cancer Therapeutics Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Vascular Malformations
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Vascular Malformations
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Vascular Malformations
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Vascular Malformations: Epidemiology Snapshot
- 5.1 Vascular Malformations Incidence by Key Markets
- 5.2 Vascular Malformations – Patients Seeking Treatment in Key Markets
- 6 Vascular Malformations: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Vascular Malformations: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Vascular Malformations, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Vascular Malformations Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Vascular Malformations Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Sirolimus
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Vascular Malformations Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: REC-994
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Other Drugs
- 12 Vascular Malformations, Key Drug Pipeline Companies
- 12.1 Vascular Therapies, Inc.
- 12.1.1 Company Snapshot
- 12.1.2 Pipeline Product Portfolio
- 12.1.3 Financial Analysis
- 12.1.4 Recent News and Developments
- 12.2 Recursion Pharmaceuticals Inc.
- 12.2.1 Company Snapshot
- 12.2.2 Pipeline Product Portfolio
- 12.2.3 Financial Analysis
- 12.2.4 Recent News and Developments
- 12.3 Vesper Medical, Inc.
- 12.3.1 Company Snapshot
- 12.3.2 Pipeline Product Portfolio
- 12.3.3 Financial Analysis
- 12.3.4 Recent News and Developments
- 12.4 Sonavex, Inc.
- 12.4.1 Company Snapshot
- 12.4.2 Pipeline Product Portfolio
- 12.4.3 Financial Analysis
- 12.4.4 Recent News and Developments
- 12.5 VenoStent
- 12.5.1 Company Snapshot
- 12.5.2 Pipeline Product Portfolio
- 12.5.3 Financial Analysis
- 12.5.4 Recent News and Developments
- 12.6 Medtronic Endovascular
- 12.6.1 Company Snapshot
- 12.6.2 Pipeline Product Portfolio
- 12.6.3 Financial Analysis
- 12.6.4 Recent News and Developments
- 12.7 VentureMed Group Inc.
- 12.7.1 Company Snapshot
- 12.7.2 Pipeline Product Portfolio
- 12.7.3 Financial Analysis
- 12.7.4 Recent News and Developments
- 13 Regulatory Framework for Drug Approval, By Region
- 14 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
